Cytomegalovirus Immune Globulin and Seronegative Blood Products to Prevent Primary Cytomegalovirus Infection after Marrow Transplantation
- 17 April 1986
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 314 (16), 1006-1010
- https://doi.org/10.1056/nejm198604173141602
Abstract
In an attempt to prevent primary cytomegalovirus infection after marrow transplantation, we randomly assigned 97 patients who were seronegative for antibody to cytomegalovirus before transplantation to receive one of the following: (1) both intravenous cytomegalovirus immune globulin and seronegative blood products (23 patients); (2) seronegative blood products alone (28 patients); (3) globulin alone (22 patients); or (4) neither treatment (24 patients). Patients not assigned to receive seronegative blood products received unscreened blood products from random donors. The incidence of cytomegalovirus infection according to study group among patients in the study for at least 62 days was 5 percent, 13 percent, 24 percent, and 40 percent, respectively. Among 57 patients with seronegative marrow donors, those who received seronegative blood products had significantly less infection (1 of 32) than those who received standard blood products (8 of 25, P<0.007). In contrast, the use of seronegative blood products did not appear to prevent cytomegalovirus infection among patients with seropositive marrow donors. The possibility that cytomegalovirus immune globulin as used in this study can prevent cytomegalovirus infection or ameliorate cytomegalovirus disease was not confirmed, and it cannot be recommended for routine use without additional study. (N Engl J Med 1986; 314:1006–10.)Keywords
This publication has 14 references indexed in Scilit:
- Risk Factors for Cytomegalovirus Infection after Human Marrow TransplantationThe Journal of Infectious Diseases, 1986
- Prevention of transfusion‐associated cytomegalovirus infection in very low‐birthweight infants using frozen blood and donors seronegative for cytomegalovirusTransfusion, 1984
- Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin: Randomized trial in bone marrow transplant recipientsAmerican Journal Of Medicine, 1984
- Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation: Preliminary results of a controlled trialAmerican Journal Of Medicine, 1984
- TOWNE-VACCINE-INDUCED PREVENTION OF CYTOMEGALOVIRUS DISEASE AFTER RENAL TRANSPLANTSThe Lancet, 1984
- Infections Due to Herpesviruses in Cardiac Transplant Recipients: Role of the Donor Heart and Immunosuppressive TherapyThe Journal of Infectious Diseases, 1983
- Prevention of Cytomegalovirus Infection by Cytomegalovirus Immune Globulin After Marrow TransplantationAnnals of Internal Medicine, 1983
- Prevention of transfusion-acquired cytomegalovirus infections in newborn infantsThe Journal of Pediatrics, 1981
- Cytomegalovirus Infection in Dialysis Patients and PersonnelAnnals of Internal Medicine, 1978
- SEROEPIDEMIOLOGY OF INFECTIONS DUE TO MEMBERS OF THE HERPESVIRUS GROUPAmerican Journal of Epidemiology, 1971